CHEMOTHERAPY OF ADRENOCORTICAL CANCER WITH o,p′DDD

Publisher Website
Google Scholar
Abstract
Ortho, prar prime-DDD [1,1-dichloro-2,2-bis(p-chlorophenyl)ethane] was given to 18 patients with metastatic adrenocortical carcinoma, resulting in objective regression of metastases in 7 patients, significant steroid suppression in 6 additional patients, and no apparent effect in 4. The average course of treatment has consisted of from 8 to 10 g of o,p'' DDD by mouth for from 4-8 weeks. There was no evidence ot toxicity to liver, kidneys or bone marrow. All patients experienced significant anorexia and nausea, and some showed central nervous depression varying from mild lethargy to somnolence. These toxic effects were reversible. Evidence was obtained that high doses of o,p'' DDD caused histologic damage and functional impairment of the normal adrenal gland.